Britt Meelby Jensen
President and Chief Executive Officer (CEO)
Britt has an M.Sc. from Copenhagen Business School, Denmark, and an MBA from Solvay Business School in Brussels, Belgium.
Britt joined Zealand as President and CEO in January 2015. Prior to joining
Zealand, she headed the Agilent-owned Danish diagnostics Company
Dako as the company’s CEO.
Britt has extensive experience from a range of managerial positions within
the life science industry, including 11 years' international experience
with Novo Nordisk. At Novo Nordisk, she held various global leadership
positions, including prelaunch commercial project lead, Diabetes
Marketing Nordic, Global Diabetes Lifecycle Management, prelaunch
commercial projects and more recently, Corporate Vice President for
Global Marketing, Market Access and Commercial Excellence.
Previously, Britt worked for McKinsey & Company and within the EU
institutions in Brussels.
Executive Vice President and Chief Financial Officer (CFO)
Mats holds a BA in Business Administration and Economics from the University of Lund, Sweden, and an MBA from IESE University of Navarra, Spain.
Prior to joining Zealand, Mats served as CFO of Swedish Orphan
International. Mats has extensive managerial experience and has held CFO positions at Active Biotech and Anoto, both publicly listed on Nasdaq Stockholm. Previously, Mats worked for several years as a management consultant at Gemini
Consulting and for Ernst & Young’s transaction services division.
Executive Vice President, Chief Medical and Development Officer (CMDO)
Adam is a certified medical doctor and holds a
Doctor of Medical Sciences degree (D.M.Sc./dr.med.) from the University of Copenhagen, Denmark, and an MBA from IMD, Switzerland. Adam has published more than 45 peer-reviewed scientific papers in renowned international journals.
Prior to joining Zealand, Adam led clinical research teams as Medical
Director at Novo Nordisk and worked as a clinician at the University
Hospital of Copenhagen, Denmark. Adam has served as a medical and
scientific adviser within endocrinology, cardiology, gastroenterology and
Executive Vice President and Chief Science Officer (CSO)
Andrew holds a Ph.D. from the National Institute for Medical Research in Mill Hill, London, UK. He conducted postdoctoral research at Johns Hopkins School of Medicine, Baltimore, U.S., and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 peer-reviewed scientific papers in renowned international journals.
Prior to joining Zealand, Andrew Parker was General Partner and Scientific
Director for Eclosion2. At the same time, he was CEO of Arisgen SA, an Eclosion2
portfolio company developing an oral peptide drug delivery technology.
Andrew Parker worked as Vice President and Head of Exploratory Projects for Shire plc.